Fortress biotech, inc. (FBIOP)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10
Revenue
Product revenue, net

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue, net

-

-

-

0

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue - related party

2,328

1,708

4,664

4,389

3,464

3,506

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net revenue

43,070

36,629

34,490

29,891

27,456

26,882

-107,129

-65,416

-21,534

17,245

0

0

0

-

0

0

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Net revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,023

863

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross margin

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Cost of goods sold - product revenue

0

-

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold - product revenue

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

66,830

75,236

72,437

75,354

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development - licenses acquired

5,890

6,090

5,056

4,357

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold - product revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

29,810

0

0

0

-

15,025

18,777

24,195

25,682

23,715

22,131

18,861

17,468

16,325

14,301

11,918

8,583

6,963

0

0

0

Research and development - licenses acquired

-

-

-

-

-

-

-

-

2,967

4,164

5,483

6,483

6,743

5,532

3,669

4,564

4,052

11,408

10,882

8,987

7,439

0

0

0

0

-

-

-

0

-

-

-

0

20,706

0

0

0

-

General and administrative

-

-

-

0

-

-

-

0

0

-

-

0

0

-

0

0

-

18,734

0

0

0

-

10,190

9,596

9,709

10,098

9,797

9,708

9,149

8,665

7,784

7,508

7,162

5,755

4,225

0

0

0

Underwriting costs

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

148,216

-

-

-

43,180

84,857

107,041

247,490

185,222

128,698

82,190

63,302

64,178

54,574

51,394

43,391

29,640

26,641

20,652

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-99,739

-110,819

-112,660

-118,325

-118,433

-119,997

-104,198

-108,596

-106,391

-89,796

-92,610

-76,253

-68,196

-65,710

-59,099

-60,925

-53,551

-50,531

-42,866

-29,140

-26,141

-20,652

-25,215

-28,373

-33,904

-35,780

-34,555

-32,882

-29,053

-27,176

-24,109

-21,809

-19,080

-35,044

-31,894

0

0

0

Other income (expense)
Interest income

2,748

2,559

2,218

1,749

1,264

1,104

1,130

1,065

961

819

587

472

359

298

291

241

238

245

340

469

566

662

0

0

0

-

-

348

268

236

206

197

190

165

135

0

0

0

Interest expense and financing fee

12,505

11,849

11,433

10,922

10,406

10,340

10,039

10,602

9,392

7,687

7,150

4,619

3,768

3,690

2,188

1,851

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense and financing fee

12,505

11,849

11,433

10,922

10,406

10,340

10,039

10,602

9,392

7,687

7,150

4,619

3,768

3,690

2,188

1,851

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

0

-

-

-

705

682

5,409

6,060

4,687

368

-4,221

-4,844

-3,392

1,039

543

527

527

438

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of subsidiary convertible note

-

-

-

-

-

437

-72

-62

-110

-457

-424

-363

-175

-78

-13

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of subsidiary convertible note

-

-

-

-

-

437

-72

-62

-110

-457

-424

-363

-175

-78

-13

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,903

1,593

1,127

670

240

76

76

74

117

0

0

0

Change in fair value of investments

-

-

-

-

-

-1,390

-923

-88

776

226

488

137

-821

-1,071

-3,410

-4,801

-2,378

-1,675

1,170

2,349

727

942

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on deconsolidation of Caelum

92

18,476

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expenses

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of short-term investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

Total other income (expense)

-9,734

9,159

9,322

8,727

7,520

-10,803

-15,664

-16,343

-12,702

-7,717

-2,510

484

-1,013

-5,580

-5,964

-7,037

-4,440

-3,352

345

1,882

590

266

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-103,338

-109,598

-

-130,800

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued operations:
Loss from discontinued operations, net of tax

-

-

-

-

-

-13,469

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total loss from discontinued operations

-

-

-

-

-

-11,136

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax expense

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-109,473

-101,660

-108,120

-111,737

-119,973

-141,936

-128,539

-136,259

-123,492

-99,836

-95,120

-75,769

-69,209

-71,290

-65,063

-67,962

-57,991

-53,883

-42,521

-27,258

-25,551

-20,386

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Less: net loss attributable to non-controlling interests

-55,751

-61,700

-58,772

-58,513

-58,236

-57,789

-58,859

-56,101

-47,580

-32,960

-21,226

-16,010

-14,337

-16,195

-15,363

-13,082

-9,414

-5,455

-2,416

-722

-479

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

0

-

-

-

Net income (loss) attributable to common stockholders

-53,722

-39,960

-49,348

-53,224

-61,737

-84,147

-69,680

-80,158

-75,912

-66,876

-73,894

-59,759

-54,872

-55,095

-49,700

-54,880

-48,577

-48,428

-40,105

-26,536

-25,072

-20,386

-26,471

-29,711

-35,670

-37,158

-36,024

-34,127

-29,912

-27,610

-25,665

-23,095

-20,373

-36,360

-31,761

0

0

0

Net loss per common share - basic

-0.38

-

-

-

-0.34

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per common share - diluted

-0.38

-

-

-

-0.25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations per common share - basic and diluted

-

-

-0.44

-0.51

-

-0.80

-0.70

-0.66

-0.85

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from discontinued operations per common share - basic and diluted

-

-

-

-

-

-0.11

0.06

-0.16

-0.05

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per common share attributable to common stockholders - basic

-0.19

-

-

-

0.03

-

-

-

-0.49

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per common share attributable to common stockholders - diluted

-0.19

-

-

-

0.02

-

-

-

-0.49

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding - basic

63,496

-

-

-

48,506

-

-

-

42,518

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding - diluted

63,496

-

-

-

63,811

-

-

-

42,518

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common Stock dividend to Series A Convertible Preferred Stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

0

-

-

Net loss attributed to Common Stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-25,665

-23,095

-26,234

-42,221

-37,622

0

0

0

Net loss per common share attributable to common stockholders - basic and diluted

-

-

-0.22

-0.24

-

-

-0.37

-0.50

-

-0.21

-0.67

-0.43

-0.30

-0.44

-0.32

-0.31

-0.31

-0.31

-0.46

-0.16

-0.31

-0.09

-0.13

-0.13

-0.21

-0.25

-0.24

-0.38

-0.35

-0.34

-0.24

-0.34

-0.35

1.32

-0.48

-1.64

-4.71

-0.44

Weighted average common shares outstanding - basic and diluted

-

-

56,856

53,726

-

-

44,818

43,377

-

45,001

40,724

40,551

40,357

40,196

40,128

39,867

39,658

39,479

39,412

39,119

38,574

37,363

36,024

36,005

35,900

35,806

32,634

28,095

25,182

24,445

24,375

19,194

18,604

12,984

7,028

5,848

4,791

4,791